Seeking Alpha

Hikma buys Boehringer's injectable drugs business

  • Hikma Pharmaceuticals (HKMPF) has agreed to buy the U.S. generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300M, as it attempts to boost its "injected medicine" market share.
  • The company will pay $225M upfront for the assets of Boehringer's Bedford Laboratories and another $75M over the course of five years based on the performance of the drugs.
This was corrected on 05/28/2014 at 09:11 AM.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector